Introduction {#Sec1}
============

Currently, lung cancer still has the highest incidence among malignant tumours, and NSCLC is the most common type. Although the mortality rate of lung cancer has decreased compared with the past, the five-year survival rate is still not high \[[@CR1], [@CR2]\]. In China, lung cancer has also long been the leading cause of cancer-related death, and there are a large number of new cases every year \[[@CR3], [@CR4]\]. Furthermore, with the promotion of low-dose computed tomography scans and the public's attention to routine health examinations, more and more patients with early-stage NSCLC have emerged in clinical practice \[[@CR5]\]. Improving the therapeutic effect for these patients has great significance for improving the survival rate of lung cancer.

For patients with early-stage NSCLC, especially with stage IA disease, surgical resection has always been the primary choice \[[@CR6], [@CR7]\]. However, the management of mediastinal lymph nodes during surgery remains controversial. Although early-stage NSCLC patients have been recommended for lobectomy with MLND for years, recent studies have shown that the benefit of other lymph node treatments is not inferior to MLND \[[@CR8]--[@CR10]\]. It is not clear whether MLND should be performed in stage IA NSCLC patients who undergo lobectomy \[[@CR10]--[@CR12]\].

In addition, with the development of improved treatment modalities and techniques, the impact of treatment on the prognosis of NSCLC patients has changed \[[@CR13], [@CR14]\], but little is known about the time trend of surgery in NSCLC patients still. In the past, most researchers focused on the surgical resection of the lung and the management of lymph nodes in early-stage NSCLC patients \[[@CR15], [@CR16]\], but they paid less attention to the time trend effect of surgery in early-stage patients, which is important for revealing NSCLC treatment progress. In particular, in the past decade, minimally invasive techniques and targeted therapy and immunotherapy for tumours have had a significant impact on the therapeutic effects for NSCLC patients. In early-stage NSCLC patients, this time trend effect should be considered.

The International Association for the Study of Lung Cancer (IASLC) released the eighth edition of the tumour, node, and metastasis (TNM) classification of lung cancer in 2016, and one of the changes is that the T1 stage is subdivided into T1a, T1b, and T1c \[[@CR17]\]. In addition, the surgical outcomes of patients with NSCLC also change over time \[[@CR18], [@CR19]\]. However, there is little knowledge about the differences in surgical treatment and time trends among these new early-stage NSCLC patients. In this study, we compare the clinical efficacy of lobectomy and lobectomy with MLND in stage T1a, T1b and T1c NSCLC patients and time trends based on patients in the SEER database.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

This study included patients who were diagnosed with stage IA (T1a/1b/1cN0M0) NSCLC from 2003 to 2013 and had integrated clinical data in the SEER database. The patients underwent either lobectomy or lobectomy with MLND. The histological type of lung-cancer was confined to squamous cell carcinoma and adenocarcinoma (SEER codes 8170 and 8140). TNM classification of NSCLC was according to the eighth edition of the IASLC International Staging Project \[[@CR17]\]. The exclusion criteria were as follows: 1) more than one primary tumour or coexisting multiple tumours; and 2) primary tumour sites in the main bronchus, overlapping lung lesion, and unknown sites.

Survival time was defined as the period between the date of diagnosis and the day of death. OS and LCSS were used as the main outcome events. If patients were still alive at the study cut-off date, they were regarded as censored cases.

Statistical analysis {#Sec4}
--------------------

Categorical covariance and continuous covariance were analysed by the chi-square test and independent sample t test, respectively. The Kaplan--Meier method was utilized to show the OS distribution and LCSS distribution. A Log-rank test was used to test for significant differences between the two groups. We used the Cox proportional hazards model to perform univariate and multivariate analyses. Predictors (*P* \< 0.15) identified in univariate analyses were entered into a multivariable analysis. All the data were analysed using SPSS 19.0 software (SPSS Inc., Chicago, USA) and Graph Pad Prism 5 (Graph Pad Software Inc., La Jolla, USA). *P* \< 0.05 was considered statistically significant.

Results {#Sec5}
=======

In this study, we enrolled 8631 stage IA NSCLC patients who underwent lobectomy or lobectomy with MLND between 2003 and 2013 totally and grouped these patients into the lobectomy group and lobectomy with MLND group. Based on tumour size and time of diagnosis, these patients were divided into six groups for stratified studies. The baseline characteristics of stage IA (T1a, T1b, and T1c) NSCLC patients who underwent surgery between 2003 and 2013 are listed in Table [1](#Tab1){ref-type="table"}, Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}. Perhaps due to patient stratification, there were almost no significant differences in these preoperative variables between the lobectomy group and the lobectomy with MLND group, except for the primary site of the tumour in Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}. Table 1Baseline characteristics of T1a NSCLC patients who were diagnosed in 2003--2013VariablesPeriod between 2003 and 2008Period between 2009 and 2013Lobectomy\
(*n* = 98)Lobectomy with MLND (*n* = 215)*p*Lobectomy\
(*n* = 82)Lobectomy with MLND (*n* = 295)*p*Mean ± SD Age (years)63.55 ± 9.5665.53 ± 8.830.0864.51 ± 10.4564.65 ± 9.080.91Sex, no. (%)0.090.15male46 (46.9)79 (36.7)36 (43.9)104 (35.3)female52 (53.1)136 (63.3)46 (56.1)191 (64.7)Race, no. (%)0.900.89White88 (89.8)192 (89.3)67 (81.7)243 (82.4)Black/ Others10 (10.2)23 (10.7)15 (18.3)52 (17.6)Histology, no. (%)0.670.22Squamous cell carcinoma30 (30.6)71 (33.0)15 (18.3)73 (24.7)Adenocarcinoma68 (69.4)144 (67.0)67 (81.7)222 (75.3)Grade, no. (%)0.180.71I16 (16.3)42 (19.5)24 (29.3)91 (30.8)II59 (60.2)99 (46)34 (41.5)135 (45.8)III19 (19.4)59 (27.4)22 (26.8)59 (20.0)IV01 (0.5)01 (0.3)Unknown4 (4.1)14 (6.5)2 (2.4)9 (3.1)Primary site of tumor, no. (%)0.860.71Upper lobe70 (71.4)147 (68.4)51 (62.2)192 (65.1)Middle lobe6 (6.1)15 (7.0)8 (9.8)21 (7.1)Lower lobe22 (22.4)53 (24.7)23 (28)82 (27.8)Laterality, no. (%)0.310.94Left39 (39.8)72 (33.5)29 (35.4)103 (34.9)Right59 (60.2)143 (66.5)53 (64.6)192 (65.1)*SD* Standard deviationT1a 0 \< tumor size≤1 cmTable 2Baseline characteristics of T1b NSCLC patients who were diagnosed in 2003--2013VariablesPeriod between 2003 and 2008Period between 2009 and 2013Lobectomy\
(*n* = 703)Lobectomy with MLND (*n* = 1333)*p*Lobectomy\
(*n* = 484)Lobectomy with MLND (*n* = 1838)*p*Mean ± SD Age (years)66.94 ± 9.6666.10 ± 9.710.0666.98 ± 9.2966.48 ± 9.230.28Sex, no. (%)0.390.24male312 (44.4)565 (42.4)222 (45.9)788 (42.9)female391 (55.6)768 (57.6)262 (54.1)1050 (57.1)Race, no. (%)0.990.70White613 (87.2)1162 (87.2)408 (84.3)1536 (83.6)Black/ Others90 (12.8)171 (12.8)76 (15.7)302 (16.4)Histology, no. (%)0.180.46Squamous cell carcinoma215 (30.6)370 (27.8)135 (27.9)482 (26.2)Adenocarcinoma488 (69.4)963 (72.2)349 (72.1)1356 (73.8)Grade, no. (%)0.620.47I103 (14.7)177 (13.3)85 (17.6)370 (20.1)II363 (51.6)702 (52.7)251 (51.9)971 (52.8)III210 (29.9)417 (31.3)130 (26.9)444 (24.2)IVUnknown3 (0.4)4 (0.3)2 (0.4)4 (0.2)24 (3.4)33 (2.5)16 (3.3)49 (2.7)Primary site of tumor, no. (%)0.010.31Upper lobe463 (65.9)890 (66.8)308 (63.6)1198 (65.2)Middle lobe62 (8.8)66 (5.0)33 (6.8)93 (5.1)Lower lobe178 (25.3)377 (28.3)143 (29.5)547 (29.8)Laterality, no. (%)0.500.38Left283 (40.3)516 (38.7)195 (40.3)700 (38.1)Right420 (59.7)817 (61.3)289 (59.7)1138 (61.9)*SD* Standard deviationT1b 1 cm \< tumor size≤2 cmTable 3Baseline characteristics of T1c NSCLC patients who were diagnosed in 2003--2013VariablesPeriod between 2003 and 2008Period between 2009 and 2013Lobectomy\
(*n* = 563)Lobectomy with MLND (*n* = 1158)*p*Lobectomy\
(*n* = 363)Lobectomy with MLND (*n* = 1499)*p*Mean ± SD Age (years)67.60 ± 9.7668.31 ± 9.320.1467.94 ± 9.5568.13 ± 9.060.71Sex, no. (%)0.140.82male295 (52.4)563 (48.6)169 (46.6)708 (47.2)female268 (47.6)595 (51.4)194 (53.4)791 (52.8)Race, no. (%)0.930.49White489 (86.9)1004 (86.7)297 (81.8)1249 (83.3)Black/ Others74 (13.1)154 (13.3)66 (18.2)250 (16.7)Histology, no. (%)0.820.62Squamous cell carcinomaAdenocarcinoma199 (35.3)416 (35.9)127 (35.0)504 (33.6)364 (64.7)742 (64.1)236 (65.0)995 (66.4)Grade, no. (%)0.440.86I54 (9.6)131 (11.3)52 (14.3)239 (15.9)II274 (48.7)554 (47.8)186 (51.2)749 (50.0)III216 (38.4)434 (37.5)117 (32.2)467 (31.2)IV2 (0.4)11 (0.9)1 (0.3)6 (0.4)Unknown17 (3.0)28 (2.4)7 (1.9)38 (2.5)Primary site of tumor, no. (%)0.010.07Upper lobe353 (62.7)764 (66.0)214 (59.0)978 (65.2)Middle lobe37 (6.6)40 (3.5)18 (5.0)55 (3.7)Lower lobe173 (30.7)354 (30.6)131 (35.1)466 (31.1)Laterality, no. (%)0.110.54Left219 (38.9)498 (43.0)159 (43.8)630 (42.0)Right344 (61.1)660 (57.0)204 (56.2)869 (58.0)*SD* Standard deviationT1c 2 \< tumor size≤3 cm

Then, we plotted the overall survival curve and lung cancer-specific survival curve of the groups and performed a log-rank test (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). For T1a NSCLC patients, in both the period between 2003 and 2008 (Fig. [1](#Fig1){ref-type="fig"} a, b) and the period between 2009 and 2013 (Fig. [1](#Fig1){ref-type="fig"} c, d), there was no significant difference in the OS (log-rank *p* = 0.34, *p* = 0.44) and LCSS (log-rank *p* = 0.18, *p* = 0.20) between the lobectomy group and the lobectomy with MLND group. However, for stage T1b and T1c patients, the survival status was different. Between 2003 and 2008, the survival statuses of the lobectomy group and lobectomy with MLND group was significantly different in T1b patients, in terms of both OS (Fig. [2](#Fig2){ref-type="fig"} a, log-rank *p* = 0.01) and LCSS (Fig. [2](#Fig2){ref-type="fig"} b, log-rank *p* = 0.01). Nevertheless, we found that the lobectomy group and lobectomy with MLND group had different OS (Fig. [2](#Fig2){ref-type="fig"} c, log-rank *p* = 0.04), but not LCSS (Fig. [2](#Fig2){ref-type="fig"} d, log-rank *p* = 0.14), in T1b patients between 2009 and 2013. For T1c patients, we also found something different. The OS and LCSS were significantly different between 2003 and 2008 (Fig. [3](#Fig3){ref-type="fig"} a, b log-rank *p* = 0.01, log-rank *p* = 0.02) between the two groups, but not between 2009 and 2013 (Fig. [3](#Fig3){ref-type="fig"} c, d log-rank *p* = 0.60, log-rank *p* = 0.39). Fig. 1Kaplan--Meier survival curve in T1a patient groups (**a**) OS curve in period 2003--2008, (**b**) LCSS curve in period 2003--2008, (**c**) OS curve in period 2009--2013, and (**d**) LCSS curve in period 2009--2013Fig. 2Kaplan--Meier survival curve in T1b patient groups (**a**) OS curve in period 2003--2008, (**b**) LCSS curve in period 2003--2008, (**c**) OS curve in period 2009--2013, and (**d**) LCSS curve in period 2009--2013Fig. 3Kaplan--Meier survival curve in T1c patient groups (**a**) OS curve in period 2003--2008, (**b**) LCSS curve in period 2003--2008, (**c**) OS curve in period 2009--2013, and (**d**) LCSS curve in period 2009--2013

To further identify prognostic factors of the OS and LCSS in T1b and T1c patients, we performed Cox regression analyses. The factors affecting the prognosis status of patients are shown in Table [4](#Tab4){ref-type="table"}. For the OS of NSCLC patients, the factors affecting patients prognosis were age (HR = 1.04, 95% CI 1.04--1.05, *p* = 0.01), sex (HR = 0.73, 95% CI 0.67--0.79, *p* = 0.01), year of diagnosis (HR = 0.79, 95% CI 0.71--0.87, *p* = 0.01), histology (HR = 0.76, 95% CI 0.70--0.83, *p* = 0.01) and grade (HR = 1.13, 95% CI 1.08--1.19, *p* = 0.01). The factors affecting the LCSS of patients were age (HR = 1.03, 95% CI 1.02--1.04, *p* = 0.01), sex (HR = 0.76, 95% CI 0.68--0.85, *p* = 0.01), year of diagnosis (HR = 0.73, 95% CI 0.64--0.84, *p* = 0.01),and grade (HR = 1.20, 95% CI 1.12--1.28, *p* = 0.01). Table 4Cox regression analyses for OS and LCSS in T1b and T1c NCSLC patients who underwent Lobectomy or Lobectomy with MLND between 2003 and 2013variablesOSLCSSpExp(B)95.0% CI for Exp(B)PExp(B)95.0% CI for Exp(B)LowerUpperLowerUpperAge0.011.0421.0371.0470.011.031.021.04Sex0.010.7290.6710.7930.010.760.680.85Year of diagnosis0.010.7860.7090.8710.010.730.640.84Histology0.010.7580.6950.828--------Grade0.011.1321.0761.1910.011.201.121.28OS overall survival LCSS lung cancer specific survivalHR hazard ratio CI confidence interval

Discussion {#Sec6}
==========

The treatment of mediastinal lymph nodes in NSCLC patients has always been controversial, especially in patients with early-stage NSCLC. The European Society of Thoracic Surgeons (ESTS) guidelines recommend the sampling or dissection of systemic lymph nodes in all lung cancer patients, but the National Comprehensive Cancer Network (NCCN) and the American College of Chest Physicians (ACCP) did not exclude other treatments of mediastinal lymph nodes in NSCLC patients \[[@CR20]--[@CR22]\]. In this study, our results indicated that as time progresses and treatments advance, the survival rate of stage IA NSCLC patients who underwent lobectomy was not inferior to patients who underwent lobectomy with MLND. In particular, the benefit of lobectomy in T1a NSCLC patients has always been noninferior to lobectomy with MLND, but this is not the case in T1b and T1c NSCLC patients. Therefore, stage IA NSCLC patients may undergo lobectomy for surgical resection. Of course, this needs to be confirmed by larger prospective randomized controlled studies in the future.

Darling GE et al. showed that for N0 NSCLC patients with negative results from the systematic sampling of mediastinal lymph nodes, MLND does not improve survival in these patients with early-stage NSCLC patients \[[@CR10]\]. Hiroyuki et al. also indicated that the OS and LCSS of lobe-specific nodal dissection were roughly equivalent to those of MLND in early-stage NSCLC patients \[[@CR10]\]. These conclusions are consistent with our findings. However, some studies have also noted that there is a phenomenon of skipping metastasis in lymph node metastasis of NSCLC, even in stage IA patients, and the mediastinal lymph node dissection can obtain accurate staging and provide guidance for postoperative chemotherapy and radiotherapy \[[@CR23]--[@CR25]\]. Indeed, we do not deny the superiority of mediastinal lymph node dissection in N stage patients with NSCLC, but the incidence of skipping metastasis in patients with stage IA NSCLC is not high. In addition, as an increasing number of targeted therapies achieve very good clinical results, these methods are a good complement to the inaccuracies of N stage in surgery. Considering the potential for injuring of the recurrent laryngeal nerve and esophagus, and possible complications caused by MLND, lobectomy with MLND is not the most appropriate choice for all patients with stage IA NSCLC.

In addition, there were also researchers hold the opinion that for potentially better survival, patients who are intraoperatively identified as stage T1 with lesions between 2 and 3 cm should undergo systematic MLND, and patients with lesions of 2 cm or less should undergo mediastinal lymph node sampling \[[@CR26], [@CR27]\]. However, the significant differences between this study and the study above are that the sample size and study time. Therefore, we took advantage of the SEER database and conducted a large-scale retrospective study to compare the time trend between the lobectomy group and lobectomy with the MLND group. We found that lobectomy with MLND is not superior in terms of postoperative survival compared to lobectomy in stage T1 NSCLC patients with lesions between 2 and 3 cm or with fewer lesions. Certainly, this finding was due to many factors. For example, with the advancement of surgical techniques, such as video-assisted thoracoscopic surgery (VATS) and Da Vinci surgical robot, lobectomy has become increasingly minimally invasive and rapid \[[@CR28]--[@CR30]\]. However, MLND may inevitably cause damage to the oesphagus, recurrent laryngeal nerve and other important tissues. In addition, with the rise of targeted therapy and immunotherapy, more and more advanced NSCLC patients benefit from these treatments, and to some extent, new treatments may compensate for the inaccuracy of surgical clinical staging. As the results show, the LCSS of T1b and T1c NSCLC patients differed between the lobectomy group and lobectomy with MLND group in the period 2003--2008. However, there was no difference between the two groups in the period from 2009 to 2013. This is a reflection of the time trends. To the best of our knowledge, this is the first time a study has evaluated the impact of mediastinal lymph node dissection on the prognosis of T1a, T1b, and T1c NSCLC patients undergoing lobectomy respectively according to the eighth edition of the lung cancer staging criteria.

This study also had some limitations. For example, the SEER database did not have pathological data regarding the postoperative N stage, so we were unable to determine the effect of the two surgical procedures on the postoperative N stage. In addition, there are no preoperative and postoperative chemotherapy data in the database, which will have a certainly impact the judgment of the results. Moreover, although this is a large-scale data study, it is a retrospective study, and the results are not as convincing as large-scale prospective multicentre studies.

In conclusion, our results suggest that for stage IA NSCLC patients, lobectomy was not inferior to lobectomy with MLND in T1 NSCLC patients. Moreover, the opposite result was found in the study periods between 2003 and 2008 and study period between 2009 and 2013 for T1b and T1c NCSLC patients, which means that there is a time trend of the effect that two surgical procedures have on these patients that we should pay attention to.
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